Myelofibrosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019 On 3rdJanuary 2015
Summary The industry analysis specialist, has released its new report, “Myelofibrosis Therapeutics Pipeline Assessment and Market Forecasts to 2019�. The report is an essential source of information and analysis on the global Myelofibrosis Therapeutics market. The report identifies the key trends shaping and driving the global Myelofibrosis Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Myelofibrosis Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
You can buy this Report @ http://www.jsbmarketresearch.com/healthcaremedical/r-myelofibrosis-therapeutics-pipeline-assessment-and-marketforecasts-135223 Scope The report provides information on the key drivers and challenges of the Myelofibrosis Therapeutics market. Its scope includes Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Myelofibrosis Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019. - Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes. - Analysis of the current and future competition in the seven key countries Myelofibrosis Therapeutics market. - Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. - Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Myelofibrosis Therapeutics market. - Analysis of key recent licensing and partnership agreements in Myelofibrosis Therapeutics market
Reasons to buy The report will enhance your decision making capability. It will allow you to - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. - Develop business strategies by understanding the trends shaping and driving the global Myelofibrosis Therapeutics market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Myelofibrosis Therapeutics market in future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. - What’s the next big thing in the global Myelofibrosis Therapeutics market landscape? – Identify, understand and capitalize. Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Other industries we cover: • • • • • • • • •
Advertising and Media Automotive and Parts Consumer Goods Healthcare and Medical Finance and Banking Food and Beverages Travel and Tourism Textiles and Clothing SWOT Analysis
Table of Content 2 Myelofibrosis Therapeutics - Introduction 2.1 Overview 2.2 Classification of Myelofibrosis 2.2.1 Primary Myelofibrosis 2.2.2 Secondary Myelofibrosis 2.3 Epidemiology 2.4 Etiology and Pathophysiology 2.4.1 Abnormalities of the Hematopoietic Stem Cells 2.4.2 Gene Mutation in JAK2 Enzyme 2.5 Risk Factors 2.6 Symptoms 2.7 Diagnosis of Myelofibrosis 2.7.1 Physical Examination 2.7.2 Full Blood Count 2.7.3 Bone Marrow Examination 2.7.4 Gene Test 2.8 Referral Pathway 2.9 Treatment 2.9.1 Allogeneic Stem Cell Transplantation 2.9.2 Treatment for Anemia 2.9.3 Treatment for Enlarged Spleen 2.9.4 Interferon Alpha 2.9.5 Cytotoxic Agents Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
2.9.6 Anagrelide 2.9.7 JAK2 Inhibitors 2.10 GlobalData Pipeline Report Guidance 3 Myelofibrosis Therapeutics - Market Characterization 3.1 Major Markets, Market Size (2006-2011) 3.2 Major Markets, Market Forecast (2011-2019) 3.3 Myelofibrosis Therapeutics Market Size (2006-2011) - The US 3.4 Myelofibrosis Therapeutics Market Forecast (2011-2019) - The US 3.5 Myelofibrosis Therapeutics Market Size (2006-2011) - The UK 3.6 Myelofibrosis Therapeutics Market Forecast (2011-2019) - The UK 3.7 Myelofibrosis Therapeutics Market Size (2006-2011) - France 3.8 Myelofibrosis Therapeutics Market Forecast (2011-2019) - France 3.9 Myelofibrosis Therapeutics Market Size (2006-2011) - Germany 3.10 Myelofibrosis Therapeutics Market Forecast (2011-2019) - Germany 3.11 Myelofibrosis Therapeutics Market Size (2006-2011) - Italy 3.12 Myelofibrosis Therapeutics Market Forecast (2011-2019) - Italy 3.13 Myelofibrosis Therapeutics Market Size (2006-2011) - Spain 3.14 Myelofibrosis Therapeutics Market Forecast (2011-2019) - Spain 3.15 Myelofibrosis Therapeutics Market Size (2006-2011) - Japan 3.16 Myelofibrosis Therapeutics Market Forecast (2011-2019) - Japan 3.17 Drivers and Barriers for the Myelofibrosis Therapeutics Market 3.17.1 Drivers of the Myelofibrosis Therapeutics Market 3.17.2 Barrier to the Myelofibrosis Therapeutics Market 3.18 Key Events Impacting the Future Market 3.19 Opportunity and Unmet Need 3.20 Key Takeaway 4 Myelofibrosis Therapeutics Market - Competitive Assessment 4.1 Overview 4.1.1 Strategic Competitor Assessment 4.2 Profiles of Commonly Used Products in the Myelofibrosis Therapeutics Market 4.2.1 5.2.1 Jakafi (ruxolitinib) 4.3 Key Takeaway 5 Myelofibrosis Therapeutics Market - Pipeline Assessment 5.1 Overview 5.2 Strategic Pipeline Assessment 5.2.1 Myelofibrosis Therapeutics - Phase III Pipeline 5.2.2 Myelofibrosis Therapeutics - Phase II Pipeline 5.2.3 Myelofibrosis Therapeutics - Phase I/II Pipeline 5.2.4 Myelofibrosis Therapeutics - Phase I Pipeline Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
5.3 Myelofibrosis Therapeutics Pipeline by Mechanism of Action 5.4 Myelofibrosis Therapeutics Technology Trends Analytical Framework 5.5 Myelofibrosis Therapeutics - Promising Drugs under Clinical Development 5.6 Molecule Profile for Late-stage under Clinical Development 5.6.1 Actimid (pomalidomide) 5.6.2 SAR302503 (TG 101348) 5.7 Key Takeaway 6 Myelofibrosis Therapeutics - Clinical Trials Mapping 6.1 Clinical Trials by Country (US, EU5 and Japan) 6.2 Clinical Trials by Phase 6.3 Clinical Trials by Trial Status 6.4 Overall Sponsors 6.5 Prominent Sponsors 6.6 Top Companies Participating in Myelofibrosis Clinical Trials 7 Myelofibrosis Therapeutics - Strategic Assessment 7.1 Myelofibrosis Therapeutics - Implications for Future Market Competition 8 Myelofibrosis Therapeutics - Future Players in the Market 8.1 Introduction 8.1.1 Sanofi 8.1.2 Celgene 8.1.3 Gilead Sciences 8.1.4 YM BioSciences Inc. 8.1.5 Novartis AG 8.1.6 S-BIO 8.1.7 Other Companies in Myelofibrosis Therapeutics Market 9 Myelofibrosis - Licensing and Partnership Deals 10 Myelofibrosis Therapeutics - Appendix 10.1 Definitions 10.2 Acronyms 10.3 Research Methodology 10.3.1 Coverage 10.3.2 Secondary Research 10.3.3 Forecasting 10.3.4 Primary Research 10.3.5 Expert Panel Validation 10.4 Contact Us 10.5 Disclaimer 10.6 Bibliography Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
List Of Tables Table 1: Myelofibrosis- Prevalence, Major Markets, 2011 Table 2: Causes of Myelofibrosis Table 3: Classification of Myelofibrosis Patients Table 4: Myelofibrosis Therapeutics Market, Major Markets, Revenue ($m), 2006-2011 Table 5: Myelofibrosis Therapeutics Market, Major Markets, Forecast ($m), 2011-2019 Table 6: Myelofibrosis Therapeutics Market, The US, Revenue ($m), 2006-2011 Table 7: Myelofibrosis Therapeutics Market, The US, Forecast ($m), 2011-2019 Table 8: Myelofibrosis Therapeutics Market, The UK, Revenue ($m), 2006-2011 Table 9: Myelofibrosis Therapeutics Market, The UK, Forecast ($m), 2011-2019 Table 10: Myelofibrosis Therapeutics Market, France, Revenue ($m), 2006-2011 Table 11: Myelofibrosis Therapeutics Market, France, Forecast ($m), 2011-2019 Table 12: Myelofibrosis Therapeutics Market, Germany, Revenue ($m), 2006-2011 Table 13: Myelofibrosis Therapeutics Market, Germany, Forecast ($m), 2011-2019 Table 14: Myelofibrosis Therapeutics Market, Italy, Revenue ($m), 2006-2011 Table 15: Myelofibrosis Therapeutics Market, Italy, Forecast ($m), 2011-2019 Table 16: Myelofibrosis Therapeutics Market, Spain, Revenue ($m), 2006-2011 Table 17: Myelofibrosis Therapeutics Market, Spain, Forecast ($m), 2011-2019 Table 18: Myelofibrosis Therapeutics Market, Japan, Revenue ($m), 2006-2011 Table 19: Myelofibrosis Therapeutics Market, Japan, Forecast ($m), 2011-2019 Table 20: Myelofibrosis Therapeutics - Phase III Pipeline Table 21: Myelofibrosis Therapeutics - Phase II Pipeline Table 22: Myelofibrosis Therapeutics - Phase I/II Pipeline Table 23: Myelofibrosis Therapeutics - Phase I Pipeline Table 24: Myelofibrosis Therapeutics - Promising Drugs under Clinical Development, 2011 Table 25: Myelofibrosis Therapeutics - Clinical Trials by Country, 2011 Table 26: Myelofibrosis Therapeutics - Clinical Trials by Phase, 2011 Table 27: Myelofibrosis Therapeutics - Clinical Trials by Status, 2011 Table 28: Myelofibrosis Therapeutics-Overall Sponsors, 2011 Table 29: Myelofibrosis Therapeutics - Prominent Sponsors, 2011 Table 30: Myelofibrosis Therapeutics - Top Companies Participating in Clinical Trials, 2011 Table 31: Sanofi - Myelofibrosis Therapeutics Pipeline Table 32: Cephalon, Inc. - Myelofibrosis Therapeutics Pipeline Table 33:Gilead Sciences Inc. - Myelofibrosis Therapeutics Pipeline Table 34: YM BioSciences Inc. - Myelofibrosis Therapeutics Pipeline Table 35: Novartis AG - Myelofibrosis Therapeutics Pipeline Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Table 36: S-BIO- Myelofibrosis Therapeutics Pipeline Table 37: Myelofibrosis Therapeutics Market- Future Players Table 38: Myelofibrosis: Licensing and Partnership Deals
List Of Figures Figure 1:Role of JAK Pathway in Myelofibrosis Figure 2: Risk Factors for Myelofibrosis Figure 3: Bone Marrow Biopsy in Myelofibrosis Figure 4: Referral Pathway Figure 5: Treatment for Low Risk and High Risk Patients of Myelofibrosis Figure 6: Treatment for Intermediate Risk Patients of Myelofibrosis Figure 7: Myelofibrosis Therapeutics Market, Major Markets, Revenue ($m), 2006-2011 Figure 8:Myelofibrosis Therapeutics Market Share ($m), 2011 Figure 9:Myelofibrosis Therapeutics Market, Major Markets, Forecast ($m), 2011-2019 Figure 10: Myelofibrosis, Market Share ($m), 2019 Figure 11:Myelofibrosis Therapeutics Market, The US, Revenue ($m), 2006-2011 Figure 12: Myelofibrosis Therapeutics Market, The US, Forecast ($m), 2011-2019 Figure 13: Myelofibrosis Therapeutics Market, The UK, Revenue ($m), 2006-2011 Figure 14: Myelofibrosis Therapeutics Market, The UK, Forecast ($m), 2011-2019 Figure 15: Myelofibrosis Therapeutics Market, France, Revenue ($m), 2006-2011 Figure 16: Myelofibrosis Therapeutics Market, France, Forecast ($m), 2011-2019 Figure 17: Myelofibrosis Therapeutics Market, Germany, Revenue ($m), 2006-2011 Figure 18: Myelofibrosis Therapeutics Market, Germany, Forecast ($m), 2011-2019 Figure 19: Myelofibrosis Therapeutics Market, Italy, Revenue ($m), 2006-2011 Figure 20: Myelofibrosis Therapeutics Market, Italy, Forecast ($m), 2011-2019 Figure 21: Myelofibrosis Therapeutics Market, Spain, Revenue ($m), 2006-2011 Figure 22: Myelofibrosis Therapeutics Market, Spain, Forecast ($m), 2011-2019 Figure 23: Myelofibrosis Therapeutics Market, Japan, Revenue ($m), 2006-2011 Figure 24: Myelofibrosis Therapeutics Market, Japan, Forecast ($m), 2011-2019 Figure 25: Myelofibrosis Therapeutics Market, Drivers and Restraints 2011 Figure 26: Opportunity and Unmet Need in the Myelofibrosis Therapeutics Market, 2011 Figure 27: Myelofibrosis Therapeutics - Pipeline by Phase of Clinical Development, 2011 Figure 28: Myelofibrosis Therapeutics Market - Clinical Pipeline by Mechanism of Action, 2011 Figure 29: Technology Trends Analytical Framework of the Myelofibrosis Therapeutics Pipeline, 2011 Figure 30: Technology Trends Analytical Framework of the Myelofibrosis Therapeutics Pipeline Description, 2011 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Figure 31: Myelofibrosis Therapeutics - Clinical Trials by Country, 2011 Figure 32: Myelofibrosis Therapeutics - Clinical Trials by Phase, 2011 Figure 33: Myelofibrosis Therapeutics - Clinical Trials by Status, 2011 Figure 34: Myelofibrosis Therapeutics - Overall Sponsors, 2011 Figure 35: Myelofibrosis Therapeutics - Prominent Sponsors, 2011 Figure 36: Myelofibrosis Therapeutics Clinical Trial - Company Sponsors by Phase, 2011 Figure 37: Implications for Future Market Competition in the Myelofibrosis Therapeutics Market, 2011 Figure 38: Myelofibrosis Therapeutics Market - Clinical Pipeline by Company, 2011
Report Price: Licence Type
Price
$ 3995
Site Licence
$ 7990
Enterprise Wide Licence
$ 11985
Related Reports: Acute Spinal Cord Injury (ASCI) Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Amnesia Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Portal Hypertension Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Hepatic Encephalopathy - Pipeline Assessment and Market Forecasts to 2019 Diabetic Gastroparesis Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Pancreatitis Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Aplastic Anemia Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Polycythemia Vera Therapeutics - Pipeline Assessment and Market Forecasts to 2019
You can order this report by calling on +91 - 998 7295 242 or mail us your contact details at contact@jsbmarketresearch.com About JSB Market Research:JSB market research is a leading player in the market of research report distribution. It is onestop-shop for all information related to market research for any sector of the industry. Along with providing in-depth analysis though reports, JSB market research also provides regular updates of the market though newsletters. Our reports are a well-researched work of market researchers with an extensive knowledge and a good level of market experience.
To know more on Myelofibrosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019 http://www.jsbmarketresearch.com/healthcare-medical/r-myelofibrosistherapeutics-pipeline-assessment-and-market-forecasts-135223
Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/